Therapeutic Prediction Model Generation for Immunotherapy Toxicity Risk
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Immunotherapy treatments for cancer, such as immune checkpoint inhibitors, pose unpredictable efficacy and toxicities, including hepatitis, pneumonitis, and colitis, due to varying patient responses and the difficulty in processing and interpreting health-related data for actionable results.
Innovation Solution
Development of AI models using Gradient Boosting and Random Forest algorithms, combined with feature engineering and data preprocessing, to predict immune-related adverse events (irAEs) like hepatitis and pneumonitis, utilizing patient data from EHRs and EMRs to align and normalize health data for robust model training and deployment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If immunotherapy is used to treat cancer, then therapeutic efficacy is improved for some patients, but toxicity and adverse side effects increase
Solution Approach 1:
The system performs preliminary assessment of patient characteristics, genomic data, and clinical history before immunotherapy administration to predict individual risk of toxicity and efficacy. This enables pre-treatment stratification to identify patients most likely to benefit while minimizing harm to those at high risk.
Solution Approach 2:
The system continuously monitors patient responses during treatment and uses feedback loops to adjust therapy parameters or intervene when toxicity thresholds are approached. This dynamic adaptation allows real-time optimization of the therapeutic benefit-harm ratio.
2Measurement precision
If patient data from multiple sources is collected for comprehensive analysis, then prediction accuracy is improved, but data processing complexity increases
Solution Approach 1:
The data processing system divides complex multi-source patient data into distinct modules: electronic health records, genomic sequencing data, imaging analyses, and laboratory results. Each module is processed independently through specialized algorithms, then integrated through standardized interfaces, reducing overall system complexity while maintaining comprehensive analysis capability.
Solution Approach 2:
The system introduces intermediate data representation layers that translate diverse data formats from different sources into a unified conceptual framework. This intermediary translation layer simplifies integration and processing by providing standardized schemas that bridge heterogeneous data sources without requiring complex direct mappings.
3Reliability
If multiple AI models are trained and evaluated to predict patient outcomes, then prediction reliability is improved, but computational resources and time required increase
Solution Approach 1:
The system trains multiple AI models with varying levels of complexity and computational resource consumption. Less resource-intensive models are used for initial screening and triage, while more resource-intensive high-precision models are deployed only for patients requiring detailed analysis. This partial application of computational resources optimizes the balance between prediction reliability and computational efficiency.
Solution Approach 2:
The system dynamically selects and switches between different AI models based on patient characteristics, data availability, and clinical urgency. For routine assessments, lighter models provide rapid predictions, while complex models are activated for high-stakes decisions or when additional data becomes available, optimizing resource allocation over time.
Data Source
AI summary
Methods, apparatus, systems, and articles of manufacture are disclosed for generation and application of models for therapeutic prediction and processing. An example apparatus includes processing circuitry to at least: process input data pulled from a record to form a set of candidate features; train a first model and a second model using the set of candidate features; test the first model and the second model to compare performance of the first model and the second model; select at least one of the first model or the second model based on the comparison; store the selected first model and/or second model; and deploy the selected first model and/or second model to predict a likelihood of at least one of: a) a toxicity occurring due to immunotherapy according to a treatment plan or b) efficacy of the treatment plan for a patient.